LB Pharmaceuticals Inc. (Nasdaq: LBRX) said it now expects to report topline results from its Phase 3 NOVA-2 clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE